Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
Active, not recruiting · NCT03620903 · Registry updated 2025-12-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2025-12-05 | NCT03620903 |
6 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Christian Buske | 5 |
| ClinAssess GmbH | 2 |
| Hoffmann-La Roche | 280 |
| Johnson & Johnson | 34 |
| University of Ulm | 46 |
| Zentrum für Klinische Studien Ulm | 4 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.